Skip to main content
OpenTrials
Completed

NCT Number: NCT01365234

Model 20066 Left Ventricular (LV) Lead Study

Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy (CRT) may be prescribed. CRT is similar to a pacemaker. It is placed (implanted) under the skin of the upper chest. CRT is delivered as tiny electrical pulses to the right and left ventricles through three leads (flexible insulated wires) that are inserted through the veins to the heart. The purpose of this study is to evaluate a new lead for delivering energy to the left ventricle (bottom left chamber of the heart).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

London, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient meets CRT inclusion criteria as determined by local regulatory and/or hospital policy
  • Patient has signed and dated the study-specific informed consent form
  • Patient is 18 years of age or older
  • Patient is expected to remain available for follow-ups at the investigational center
  • Patient is willing and able to comply with protocol

Exclusion criteria

  • Patient has a previous complete atrial based biventricular CRT system
  • Patient has a previous LV lead implanted or previous implant attempt within 30 days of implant or ongoing Adverse Events from previous unsuccessful attempt
  • Patient has known coronary venous vasculature that is inadequate for lead placement
  • Patient has unstable angina pectoris or has had an acute myocardial infarction (MI) within the past month
  • Patient has had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past three months
  • Patient has chronic (permanent) atrial arrhythmias
  • Patient has contraindications for standard transvenous cardiac pacing (e.g., mechanical right heart valve)
  • Patient has had a heart transplant (patients waiting for heart transplants are allowed in the study)
  • Patient is enrolled in any concurrent drug and/or device study that may confound the results of this study
  • Patient has a terminal illness and is not expected to survive more than three months
  • Patient meets exclusion criteria required by local law (e.g. age, incompetence, pregnancy, breast feeding, etc).
  • Patient is unable to tolerate an urgent thoracotomy

Treatment and study plan

Pacing Lead

Device

Implant and follow up of Model 20066 lead

Primary outcomes

  1. Number of implant procedure related and lead-related complications in the first month post-implant

    Time frame: One Month

Secondary outcomes

  1. Success rate of the Model 20066 lead

    Time frame: Within 24 hours of procedure initiation

  2. Cannulation time

    Time frame: Within 24 hours of procedure initiation

  3. Fluoroscopy Time

    Time frame: Within 24 hours of procedure initiation

  4. Model 20066 Lead Placement Time

    Time frame: Within 24 hours of procedure initiation

  5. Total Implant Time

    Time frame: Within 24 hours of procedure initiation

  6. Assessment of Lead Handling Characteristics

    Time frame: Within 24 hours of procedure initiation

  7. Electrical Performance-Tip Electrode: LV Voltage Threshold

    Time frame: 12-month

  8. Electrical Performance -Tip Electrode: Sensing

    Time frame: 12-month

  9. Electrical Performance -Tip Electrode: Pacing Impedance

    Time frame: 12-month

  10. Electrical Performance -Ring Electrode: LV Voltage Threshold

    Time frame: 12-month

  11. Electrical Performance -Ring Electrode: Sensing

    Time frame: Within 24 hours of procedure initiation

  12. Electrical Performance -Ring Electrode: Pacing Impedance

    Time frame: 12-month

  13. Summarize All Adverse Events

    Time frame: 12-month

  14. Summarize Final 20066 Lead Position

    Time frame: Within 24 hours of procedure initiation

Sponsors and collaborators

Lead sponsor

Medtronic Cardiac Rhythm and Heart Failure

Industry

Registry information

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jun 3, 2011
Registry last updated
Oct 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.